Literature DB >> 3783180

Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study.

R Cantello, M Gilli, A Riccio, B Bergamasco.   

Abstract

Fluctuations of mood and psychic activation were assessed in relation to "mobile" and "immobile" periods in 18 patients with Parkinson's disease presenting typical "end-of-dose deterioration". Twelve subjects with chronic but active rheumatoid arthritis presenting increased physical disability due to severe morning joint stiffness with a repetitive pattern of mobile and immobile periods acted as controls. The overall degree of disability and its fluctuations were close enough in the two groups for fair comparison of changes in affective behaviour. Temporary immobility was accompanied by adverse changes of mood and activation, which were significantly more marked in the Parkinson's disease group than in the controls, though to a lesser extent in those Parkinson's disease patients rated depressed even in their mobile periods. The possible correlation between mood changes and fluctuations of central dopaminergic function in the Parkinson's disease patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3783180      PMCID: PMC1029054          DOI: 10.1136/jnnp.49.10.1182

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  27 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Patterns of clinical response and plasma dopa levels in Parkinson's disease.

Authors:  E S Tolosa; W E Martin; H P Cohen; R L Jacobson
Journal:  Neurology       Date:  1975-02       Impact factor: 9.910

3.  Cerebral blood flow in dementia.

Authors:  V C Hachinski; L D Iliff; E Zilhka; G H Du Boulay; V L McAllister; J Marshall; R W Russell; L Symon
Journal:  Arch Neurol       Date:  1975-09

4.  Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment.

Authors:  D P Van Kammen; D L Murphy
Journal:  Psychopharmacologia       Date:  1975-11-21

5.  Endogenomorphic depression. A conceptual and terminological revision.

Authors:  D F Klein
Journal:  Arch Gen Psychiatry       Date:  1974-10

6.  Depression in rheumatoid disease.

Authors:  G Zaphiropoulos; H C Burry
Journal:  Ann Rheum Dis       Date:  1974-03       Impact factor: 19.103

7.  Retarded depression and the dopamine metabolism.

Authors:  J Korf; H M van Praag
Journal:  Psychopharmacologia       Date:  1971

8.  The Beck depression inventory with medical inpatients.

Authors:  J Schwab; M Bialow; R Clemmons; P Martin; C Holzer
Journal:  Acta Psychiatr Scand       Date:  1967       Impact factor: 6.392

9.  On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.

Authors:  I Shoulson; G A Glaubiger; T N Chase
Journal:  Neurology       Date:  1975-12       Impact factor: 9.910

10.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

View more
  14 in total

1.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

Review 2.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

3.  Neuropsychiatric phenomena associated with movement disorders.

Authors:  Joshua L Roffman; Todd Eisenberg; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 4.  Depression in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Robert A Hauser
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

5.  A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease.

Authors:  Hilary L Tyne; Jan Parsons; Ann Sinnott; Susan H Fox; Nicholas A Fletcher; Malcolm J Steiger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

Review 6.  Parkinson's disease.

Authors:  C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

Review 7.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.

Authors:  R Cantello; M Aguggia; M Gilli; M Delsedime; I Chiardò Cutin; A Riccio; R Mutani
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 9.  Treatment of depression in Parkinson's disease.

Authors:  Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin
Journal:  Curr Psychiatry Rep       Date:  2006-06       Impact factor: 5.285

Review 10.  Neuroleptic dysphoria: towards a new synthesis.

Authors:  L Voruganti; A G Awad
Journal:  Psychopharmacology (Berl)       Date:  2003-11-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.